2C-T-35

2C-T-35
Clinical data
Other names2C-T-DFM; 4-Difluoromethylthio-2,5-dimethoxyphenethylamine
Identifiers
  • 2-[4-(difluoromethylsulfanyl)-2,5-dimethoxyphenyl]ethanamine
PubChem CID
Chemical and physical data
FormulaC11H15F2NO2S
Molar mass263.30 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1CCN)OC)SC(F)F
  • InChI=1S/C11H15F2NO2S/c1-15-8-6-10(17-11(12)13)9(16-2)5-7(8)3-4-14/h5-6,11H,3-4,14H2,1-2H3
  • Key:IMXLEUNJGUBEMC-UHFFFAOYSA-N

2C-T-35, also known as 2C-T-DFM or as 4-difluoromethylthio-2,5-dimethoxyphenethylamine, is a designer drug from the substituted phenethylamine family, which was first synthesised by Josh Hartsel and colleagues in 2024. It is a potent agonist at the serotonin receptor 5-HT2A in vitro, with a binding affinity (Ki) of 6.3 nM. In animal studies, 2C-T-DFM was the most effective compound at producing a head-twitch response out of a series of related analogues, with an average of 33 head-twitches per 10 minutes compared to 21 for 2C-T-TFM. While it had previously been proposed as a theoretical compound, 2C-T-35 is not known to have been tested in humans. It is a controlled substance in Canada under phenethylamine blanket-ban language.

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.